Bayer and Kumquat Biosciences have begun a Phase-I trial of their KRAS G12D inhibitor targeting KRAS-mutated tumors, further bolstering Bayer’s precision oncology pipeline across pancreatic, colorectal, and lung cancers.
Lung Cancer | 11/10/2025 | By Dineshwori
Galvanize Therapeutics Begins Clinical Study of Aliya Pulsed Electric Field Ablation
Galvanize Therapeutics has announced the enrollment of the first patient in the PROPEL Registry, a multicenter observational study designed to evaluate the clinical application, safety, and outcomes of the Aliya Pulsed Electric Field (PEF) ablation system for soft tissue lesions.
Lung Cancer | 18/08/2025 | By Dineshwori
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy